Feb 14, 2017 12:03 pm UTC| Business
- Members of Actinium’s executive and clinical development teams to participate in conference activities and extend the visibility of the Company’s Iomab-B drug candidate to the bone marrow transplant community - BMT...
Feb 14, 2017 12:03 pm UTC| Business
- Members of Actinium’s executive and clinical development teams to participate in conference activities and extend the visibility of the Company’s Iomab-B drug candidate to the bone marrow transplant community - BMT...
AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone)
Feb 14, 2017 12:03 pm UTC| Business
Recently approved first-of-its-kind, non-estrogen prescription therapy for a common symptom of menopause ...
AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone)
Feb 14, 2017 12:03 pm UTC| Business
Recently approved first-of-its-kind, non-estrogen prescription therapy for a common symptom of menopause ...
AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone)
Feb 14, 2017 12:03 pm UTC| Business
Recently approved first-of-its-kind, non-estrogen prescription therapy for a common symptom of menopause ...
AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone)
Feb 14, 2017 12:03 pm UTC| Business
Recently approved first-of-its-kind, non-estrogen prescription therapy for a common symptom of menopause ...
Feb 14, 2017 12:02 pm UTC| Business
Six leading U.S. retinal surgery centers expected to participate as enrollment sites in the trialAnticipate beginning trial enrollment by mid-2017; interim trial update expected by the end of 2017 ROCKVILLE, Md., Feb. ...